Dynavax Technologies reported $32.46M in EBITDA for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Abbvie ABBV:US $ 7127M 482M
Adma Biologics ADMA:US $ -13.22M 1.62M
Agenus AGEN:US $ -34.34M 20.08M
Amgen AMGN:US $ 3341M 185M
Astrazeneca AZN:US $ 4187M 687M
AstraZeneca AZN:LN 4187M 687M
Biogen BIIB:US $ 674.7M 20.2M
Biomarin Pharmaceutical BMRN:US $ 56.67M 96.56M
Bristol Myers Squibb BMY:US $ 5772M 404M
Chimerix CMRX:US $ -24.75M 14.76M
Dynavax Technologies DVAX:US $ 32.46M 49.7M
Gilead Sciences GILD:US $ 3422M 1947M
Glaxosmithkline GSK:US $ 3120M 1062M
Idera Pharmaceuticals IDRA:US $ -4.18M 0.06M
Merk MRK:US $ 6179M 492M
Minerva Neurosciences NERV:US $ -7.99M 13.39M
Nektar Therapeutics NKTR:US $ -111.36M 1.88M
Neurocrine Biosciences NBIX:US $ 6.4M 60.6M
Novartis NOVN:VX SF 4552M 346M
Pfizer PFE:US $ 11182M 4046M
Regeneron Pharmaceuticals REGN:US $ 1360.9M 1353.3M
Sarepta Therapeutics SRPT:US $ -76.16M 19.51M
Tg Therapeutics TGTX:US $ -66.8M 26.07M
Vertex Pharmaceuticals VRTX:US $ 1069.3M 159.74M